Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT
UNUSUAL PRICE AND TRADING VOLUME MOVEMENT

This announcement is made by Antengene Corporation Limited (the "**Company**") on a voluntary basis to provide the shareholders (the "**Shareholders**") and potential investors of the Company with information in relation to the latest developments of the Company.

The board of directors of the Company (the "**Board**") has noted the unusual price and trading volume movements of the shares of the Company (the "**Shares**") on September 15, 2023. Having made all such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that it is not aware of any reasons for the unusual price and trading volume movements or of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company hereby states clearly and confirms that all current business of the Company remains normal, and the Company is confident in the underlying prospects for our robust clinical pipeline and for XPOVIO®, supported by the recently announced commercial partnership with Hansoh Pharmaceutical Group Company Limited ("**Hansoh Pharma**") for XPOVIO® in Mainland China, and our long-term outlook for the Company.

Notable progress has been made for each of our clinical programs, including encouraging early responses observed in our global programs with first/best-in-class potential. As of September 17, 2023:

- ATG-031 (anti-CD24 monoclonal antibody): the Institutional Review Board (IRB) of MD Anderson Cancer Center, in Houston, Texas, the lead study site for our globally first-in-class program targeting CD24 (the *planned Phase I PERFORM trial*), a unique and differentiated approach to the "don't eat me", macrophage-mediated phagocytosis (MMP) pathway, has approved the trial to proceed.

- ATG-022 (Claudin 18.2 antibody-drug conjugate): A partial response (PR) has been observed in a patient with late-stage gastric cancer in cohort 3 (1.8 mg/kg), a dose lower than the expected efficacious dose range (the *Phase I CLINCH trial*).

- ATG-101 (PD-L1/4-1BB bispecific antibody): Early data include reported PR in a patient with metastatic colon adenocarcinoma, with microsatellite stability biomarker (MSS), liver metastasis, and has received three prior lines of therapy; and two patients have been on ATG-101 for 14 and 15 cycles respectively with durable stable disease (SD) at low doses with good safety profile (the *Phase I PROBE trials*).

- ATG-037 (oral CD73 small molecule inhibitor): Reported that 13 patients (all patients previously treated with a checkpoint inhibitor (CPI)) are undergoing combination dose escalation in combination with pembrolizumab (the *Phase I STAMINA trial*). Notably, PR has been observed in a patient with melanoma previously treated with an immune CPI (anti-PD-1), and marked tumors burden reduction in another patient with non-small cell lung cancer (NSCLC) previously treated with chemo plus an immune CPI (anti-PD-1).

- ATG-008 (mTORC1/2 inhibitor): Data from the Phase II TORCH-2 study of 53 late stage metastatic cervical cancer patients, including 46 patients who had at least one tumor assessment (30 CPI-naïve and 16 CPI-pre-treated patients), the objective response rate (ORR) was 46.7% for CPI-naïve patients and 31.3% for CPI-pre-treated patients. These data compare favorably to previously published benchmark data.

Additionally, our recently announced commercial partnership with Hansoh Pharma for XPOVIO® in Mainland China is off to an excellent start. This partnership provides positive momentum and an important complement to our ongoing efforts and the potential for label expansion into significant new indications for XPOVIO®. Taken together, we believe the Company is well positioned to deliver on our mission of bringing transformative medicines to cancer patients around the world and deliver value to our Shareholders. We will continue to reporting on further progress throughout the rest of this year and early 2024 through upcoming medical meetings and investor updates.

Shareholders and potential investors of the Company are advised to exercise caution in dealing with the Shares.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, September 18, 2023

As at the date of this announcement, the Board comprises Dr. Jay Mei, Mr. John F. Chin and Mr. Donald A. Lung as executive Directors; Dr. Kan Chen as a non-executive Director; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.

About Antengene

Antengene Corporation Limited ("**Antengene**", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple APAC markets, with the NDA for XPOVIO® (selinexor) already approved in mainland China, Taiwan China, Hong Kong China, South Korea, Singapore and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to The Stock Exchange of Hong Kong Limited.